Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …

The development and approval of cyclin-dependent kinase (CDK) 4 and 6 inhibitors for
hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative …

PURPOSE To develop guideline recommendations concerning optimal neoadjuvant therapy
for breast cancer. METHODS ASCO convened an Expert Panel to conduct a systematic …

Abstract Cyclin-dependent kinase (CDK) 4/6 inhibition in combination with endocrine
therapy is the standard-of-care treatment for patients with advanced-stage hormone receptor …

Estrogen Receptor–Positive Breast Cancer ER-positive, HER2-negative breast cancer,
which accounts for about 70% of all breast cancers, is heterogeneous. Antiestrogen therapy …

The treatment of breast cancer has improved dramatically over the past century, from a
strictly surgical approach to a coordinated one, including local and systemic therapies …

Background Invasive lobular breast cancer (ILC) is the second most common type of breast
cancer after invasive breast cancer of no special type (NST), representing up to 15% of all …

Purpose: neoMONARCH assessed the biological effects of abemaciclib in combination with
anastrozole in the neoadjuvant setting. Patients and Methods: Postmenopausal women with …

Background In hormone receptor-positive, HER2-negative early stage breast cancer, cyclin-
dependent kinases 4 and 6 (CDK4/6) inhibition in combination with endocrine therapy could …

Deregulation of cell cycle, via cyclin D/CDK/pRb pathway, is frequently observed in breast
cancer lending support to the development of drugs targeting the cell cycle control …